SCHEMBL28534873

SCHEMBL28534873

COCCOc1cccc2c1CN(C(=O)O)CC2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.47
S1PR5 Q9H228 6/20 0.46
TIPARP Q7Z3E1 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ABHD6 Q9BV23 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NOTUM Q6P988 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
SCN9A Q15858 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
PDE10A Q9Y233 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21659367 0.85 ESR2 (0.47) HRH3S1PR5ABHD6SCN9APTGDR2
SCHEMBL30641865 0.84 DRD2 (0.51) HSD17B10ABHD6KMT2ANOTUMKDM4E
SCHEMBL16269151 0.83 PTGDR2 (0.53) S1PR5HPGDTSHRSMN1; SMN2HSD17B10
SCHEMBL28539714 0.76 ESR1 (0.52) HRH3HPGDTSHRSMN1; SMN2HSD17B10
SCHEMBL28533346 0.76 HRH3 (0.57) HRH3HPGDTSHRSMN1; SMN2HSD17B10
SCHEMBL22319858 0.76 ABHD6 (0.55) HRH3S1PR5HPGDTSHRSMN1; SMN2
SCHEMBL22319832 0.76 ABHD6 (0.50) HRH3S1PR5HPGDTSHRSMN1; SMN2
SCHEMBL29168677 0.76 DRD1 (0.40) HRH3HPGDTSHRSMN1; SMN2HSD17B10
SCHEMBL30726807 0.75 ALDH1A1 (0.51) HPGDSMN1; SMN2ABHD6MEN1KMT2A
SCHEMBL22319878 0.75 ABHD6 (0.54) HRH3S1PR5HPGDTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112469722-A Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists 百济神州有限公司 2021-03-09 CN disclosed